Clinical Trials Logo

Clinical Trial Summary

Goal directed therapy (GDT) is a technique, which employs a non-invasive cardiac output monitoring (NICOM) device to guide management of circulating blood volume and blood pressure during procedures. The purpose of this study is to determine whether the use of goal-directed therapy to optimize blood volume and cardiac output during the procedure can improve the outcome of patients undergoing endovascular treatment of a brain aneurysm.


Clinical Trial Description

Subarachnoid hemorrhage (SAH) as a result of ruptured intracranial cerebral aneurysms is a life threatening condition; with an estimated incidence of 6-10 cases per 100,000 persons per year. Endovascular coil emobolization of the aneurysm is performed to isolate the aneurysm and reduce the risk of re-bleeding. Unfortunately, despite timely and successful intervention approximate 25% of post-coiling patients suffer immediate and/or long-term injury including death as a result of intracranial bleeding. This is mainly a consequence of subarachnoid hemorrhage-related complications , especially cerebral vasospasm. Angiographic vasospasm and symptomatic vasospasm occur in 30-70% and 20-30% of SAH patients respectively. Goal-directed therapy (GDT) provides a means to assess and manage circulating volume and cardiac output. In this study, the investigators would investigate the use of GDT during aneurysm coiling procedures can improve the clinical course of these patients.

This will be a blinded, randomized pilot study to compare clinical outcomes for endovascular coiling patients allocated to one of two treatments: GDT or non-GDT. Randomization consented patients will be randomized into GDT or non-GDT groups in 1:1 ratio. The attending anesthesiologists will not be blinded because of the nature of the intervention. However, surgeons, patients, outcomes assessors will be blinded as to the treatment intervention.

In all patients, an arterial catheter (routinely used in these patients) will be inserted and connected to the Flotrac (Edward Lifesciences). After transferring the patients into the angiogram suite, routine monitoring such as pulse oximetry, electrocardiography, non-invasive blood pressure monitoring, end-tidal CO2 and temperature probe will be attached to the patients. Anesthesia will be conducted in the standard fashion. Patients will be randomized into two groups in 1:1 ratio: GDT or non-GDT therapy.

- GDT group: the attending anesthesiologist will use the data obtained from the Flotrac to manage fluid and hemodynamics during the procedure following the prescribed treatment algorithm. The treatment interventions will start on induction of anesthesia and continue until the patients are extubated or transferred back to intensive care unit with mechanical ventilation.

- Non-GDT group: Flotrac will be connected but the machine values will be blinded to the anesthesiologist and interventionist. The screens of the Flotrac will be covered by opaque plastic bag and the alarms will be turned off. The attending anesthesiologist will make clinical decisions regarding the management of fluids and hemodynamics based on current individual routine practices. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02507999
Study type Interventional
Source Lawson Health Research Institute
Contact
Status Completed
Phase N/A
Start date November 2015
Completion date February 2019

See also
  Status Clinical Trial Phase
Recruiting NCT04583163 - Variability in Transcranial Doppler Technique in Neuro-Critical Care Patients
Recruiting NCT03306823 - Exploration of Anticoagulation Program in Cerebral Aneurysm and Arteriovenous Malformations With Hybrid Operation 1 N/A
Recruiting NCT03306836 - Exploration of Anticoagulation Program in Cerebral Aneurysm and Arteriovenous Malformations With Hybrid Operation 2 N/A
Recruiting NCT02345395 - Safety Study of Minimally Invasive Approaches to Unruptured Anterior Circulation Aneurysms N/A
Completed NCT00962546 - Computed Tomographic (CT) Perfusion and CT Angiography as Screening Tools for Vasospasm Following Subarachnoid Hemorrhage N/A
Recruiting NCT04141020 - Effect of Sirolimus on Molecular Alterations in Cerebral Aneurysms Phase 2
Recruiting NCT01460563 - Valproic Acid, Magnesium Sulphate, Rocuronium Requirement, Postoperative Analgesia N/A
Recruiting NCT02162654 - Remote Ischemic Preconditioning for Intracranial Aneurysm Treatment N/A
Completed NCT01943591 - DELTA Trial: Does Embolization With Larger Coils Lead to Better Treatment of Aneurysms Trial N/A
Recruiting NCT03815149 - Safety and Clinical Effectiveness of Pipelineā„¢ Shield Devices for Intracranial Aneurysms
Completed NCT03152201 - New Findings About Somatosensory Evoked Potentials (SEP) During Surgery for Cerebral Aneurysms
Recruiting NCT02444832 - Multicenter Retrospective Registry of Anterior Communicating Artery Aneurysms With Endovascular Therapy N/A
Active, not recruiting NCT05774782 - Parent Artery Reconstruction for Cerebral Aneurysms Using a Novel Flow Diverter With Surface Modification N/A
Withdrawn NCT01878136 - Effect of Intraventricular tPA Following Aneurysmal Subarachnoid Hemorrhage Phase 1/Phase 2
Withdrawn NCT02011321 - Clevidipine for Vasospasm After Subarachnoid Hemorrhage (SAH) Phase 2
Completed NCT02455440 - Esmolol Infusion in Patients Undergoing Craniotomy Phase 3
Completed NCT00614887 - Hypothalamo-, Pituitary-, Adrenal Axis Dysfunction in Subarachnoid Hemorrhage
Terminated NCT02281721 - Surpass Flow Diverter for Intracranial Aneurysms: SURMOUNT Registry Data Collection
Completed NCT04963933 - A Medical Device to Treat Brain Aneurysms N/A
Completed NCT02700607 - Impact of Intravascular Fluid Resuscitation and Whole Blood Viscosity N/A